Pharmacokinetics and Safety in Healthy Volunteers

Inclusion criteria

• Male subjects aged 18 to 45 years
• Body mass index (BMI) between 19 and 26 kg/m2
• Normal or clinically acceptable physical examination, clinical laboratory values, ECG, chest X-ray and vital signs at screening and baseline.
• Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.

Exclusion criteria

• History or evidence of a clinically significant disorder, condition, or disease that would have posed a risk to subject safety or would have interfered with the study evaluation, procedures, or study completion in the opinion of the investigator.
• Evidence of any bacterial, viral, parasitic, systemic fungal infections, or infections due to other opportunistic pathogens within the 30 days prior to investigational product administration.
• History of tuberculosis,positive test for Interferon-gamma-release assay,or suffering from active tuberculosis or latent tuberculosis infection.
• History of malignancy of any type, other than surgically excised nonmelanomatous skin cancers, within 5 years prior to investigational product administration.
• Positive test for HIV antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies at screening.
• History of relevant allergy/hypersensitivity (including allergy to drug or its excipients).
• Quantification of Hepatitis B virus DNA is greater than the upper limit of normal value.
• Received biologics or live vaccines ≤3 months prior to investigational product administration.
• Intake of an investigational drug in another trial within three months prior to investigational product administration.